CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液学与肿瘤学急症综述
英文原题：Review of Hematological and Oncological Emergencies.
查看英文原题
Review of Hematological and Oncological Emergencies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
接受治疗或尚未治疗的血液系统恶性肿瘤患者，以及正在接受治疗的实体瘤患者，均可能发生危及生命的并发症并需要急诊处理。这些急症病因多样，通常需要及时治疗。发热性中性粒细胞减少等传统并发症的指南近期有所更新，纳入了新证据和经过验证的新型风险分层工具。此外，嵌合抗原受体（CAR）T细胞治疗等新疗法日益普及，也带来了独特的相关毒性。本综述讨论急诊科可能遇到的血液肿瘤及肿瘤急症的处理，包括发热性中性粒细胞减少、CAR-T 细胞毒性、分化综合征、肿瘤溶解综合征、恶性肿瘤相关高钙血症和低钠血症。
展开英文摘要原文
Patients with hematological malignancies, both treated and untreated, or solid tumors undergoing treatment are at risk of life-threatening complications, which may present in the emergency department (ED). Such emergencies are diverse in etiology and often require prompt treatment. Traditional complications, such as febrile neutropenia, have had recent guideline updates, which incorporate new evidence and a new validated risk stratification tool.
In addition, newer approaches to treatment, such as chimeric antigen receptor (CAR) T-cell therapy, are becoming more widely available and have unique associated toxicities. This review discusses the management of the following hematological and oncological emergencies likely to be encountered in the ED: febrile neutropenia, CAR T-cell toxicities, differentiation syndrome, tumor lysis syndrome, hypercalcemia of malignancy, and hyponatremia.
论文信息
- 作者
- Barré S、McElwee J、Calhoun C、Weant KA、Maldonado A、Bell CM
- 第一作者单位
- Ochsner Louisiana State University Health, Shreveport (Dr Barré); Atrium Health's Carolinas Medical Center, Charlotte, North Carolina (Dr McElwee); Medical University of South Carolina, Charleston (Drs Calhoun, Maldonado, and Bell); and Department of Clinical Pharmacy and Outcome Sciences, University of South Carolina College of Pharmacy, Columbia (Dr Weant).
- 文献类型
- 综述
- 期刊
- Advanced emergency nursing journal2022 Apr-Jun 01
- 原文标识
- PubMed 35476684 · DOI 10.1097/TME.0000000000000399